{"id":915500,"date":"2025-12-02T17:29:01","date_gmt":"2025-12-02T22:29:01","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/hyperliquid-strategies-inc-and-sonnet-biotherapeutics-holdings-inc-announce-closing-of-business-combination\/"},"modified":"2025-12-02T17:29:01","modified_gmt":"2025-12-02T22:29:01","slug":"hyperliquid-strategies-inc-and-sonnet-biotherapeutics-holdings-inc-announce-closing-of-business-combination","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/hyperliquid-strategies-inc-and-sonnet-biotherapeutics-holdings-inc-announce-closing-of-business-combination\/","title":{"rendered":"Hyperliquid Strategies Inc and Sonnet BioTherapeutics Holdings, Inc. Announce Closing of Business Combination"},"content":{"rendered":"<h2>\nHyperliquid Strategies Common Stock Expected to Begin Trading on Nasdaq on Wednesday, December 3 Under the Ticker \u201cPURR\u201d<br \/>\n<\/h2>\n<div class=\"mw_release\">\n<p align=\"justify\">NEW YORK and PRINCETON, N.J., Dec.  02, 2025  (GLOBE NEWSWIRE) &#8212; Hyperliquid Strategies Inc (\u201cHSI\u201d or the \u201cCompany\u201d) and Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) (\u201cSonnet\u201d) today announced the completion of the closing of the previously announced business combination among HSI, Sonnet and Rorschach I LLC (\u201cRorschach\u201d), a newly-formed entity formed by an entity affiliated with Atlas Merchant Capital LLC (\u201cAtlas\u201d), an affiliate of Paradigm Operations LP (\u201cParadigm\u201d), and additional sponsors (all together, the \u201cSponsors\u201d), which was approved by Sonnet\u2019s stockholders on December 2, 2025.<\/p>\n<p align=\"justify\">As a result of the closing, the Company will operate as a HYPE digital asset treasury reserve company, and Sonnet will continue to operate as a wholly-owned subsidiary of the Company. HSI\u2019s common stock is expected to begin trading on The Nasdaq Capital Market under the ticker symbol \u201cPURR\u201d on Wednesday, December 3, and Sonnet\u2019s common stock will no longer trade.<\/p>\n<p align=\"justify\">Under the terms of the business combination, shares received by shareholders of Sonnet and members of Rorschach were adjusted for a five-for-one exchange ratio.<\/p>\n<p align=\"justify\">HSI will be led by David Schamis as Chief Executive Officer. The Company\u2019s board of directors will consist of Bob Diamond, David Schamis, Jeff Tuder, Eric Rosengren, Thomas King, Larry Leibowitz, Nailesh Bhatt and Albert Dyrness.<\/p>\n<p align=\"justify\">\u201cWe are thrilled to have completed this business combination, allowing US equity investors to gain exposure to the HYPE token through our digital asset treasury strategy with a large, highly liquid listing,\u201d said Bob Diamond, Chairman of HSI.<\/p>\n<p align=\"justify\">David Schamis, CEO of HSI said, \u201cThe Hyperliquid blockchain was built to house all finance. It has rapidly become one of the highest-revenue-generating blockchains in the world. The Hyperliquid decentralized exchange is a market leader in perpetual futures and spot trading that is used by hundreds of thousands of traders around the world, processing billions in daily trading volume. Today marks a watershed moment: U.S. public market investors can now participate directly in the Hyperliquid ecosystem and do so through a highly liquid, publicly traded vehicle.\u201d<\/p>\n<p align=\"justify\">\u201cHyperliquid\u2019s approach to high-performance, decentralized trading has attracted substantial volumes from a growing community of traders and developers,\u201d said Paradigm Managing Partner Alana Palmedo. \u201cHyperliquid Strategies provides an innovative vehicle for investors to gain exposure to this emerging network.\u201d<\/p>\n<p align=\"justify\">Chardan acted as sole placement agent to the transaction and exclusive financial advisor to Rorschach in connection with the transaction. Greenberg Traurig, LLP served as legal counsel to HSI in connection with the transactions and Lowenstein Sandler LLP served as legal counsel to Sonnet. Lucid Capital Markets, LLC provided a fairness opinion to Sonnet\u2019s board of directors.<\/p>\n<p align=\"justify\">\n        <strong>About Hyperliquid Strategies Inc<\/strong>\n      <\/p>\n<p align=\"justify\">Hyperliquid Strategies Inc (NASDAQ: PURR) is a digital asset treasury company whose primary focus is to maximize shareholder value through accumulating HYPE, the native token of Hyperliquid, a high-performance blockchain custom-built to house all of finance. HSI aims to provide capital-efficient and productive access to the HYPE token for U.S. and institutional investors, generating compounding shareholder returns that individual holders may not be able to replicate through staking, yield optimization, and active ecosystem engagement. HSI is positioned to become the largest HYPE-focused digital asset treasury vehicle capitalizing on Hyperliquid&#8217;s rapid growth and providing exposure to one of the largest and fastest growing revenue pools in digital assets. For more information, please visit www.hypestrat.xyz .<\/p>\n<p align=\"justify\">\n        <strong>About Sonnet BioTherapeutics Holdings, Inc.<\/strong>\n      <\/p>\n<p align=\"justify\">Sonnet BioTherapeutics Holdings, Inc. is an oncology-focused biotechnology company with a proprietary platform for innovating biologic drugs of single or bifunctional action. Known as FHAB (Fully Human Albumin Binding), the technology utilizes a fully human single chain antibody fragment (scFv) that binds to and \u201chitch-hikes\u201d on human serum albumin (HSA) for transport to target tissues. Sonnet\u2019s FHAB was designed to specifically target tumor and lymphatic tissue, with an improved therapeutic window for optimizing the safety and efficacy of immune modulating biologic drugs. FHAB is the foundation of a modular, plug-and-play construct for potentiating a range of large molecule therapeutic classes, including cytokines, peptides, antibodies, and vaccines. For more information, please visit Sonnetbio.com.<\/p>\n<p>\n        <strong>About Atlas Merchant Capital LLC<\/strong>\n      <\/p>\n<p align=\"justify\">Atlas Merchant Capital LLC was founded to participate in compelling market opportunities in the financial services sector. Based in New York and London, Atlas Merchant Capital was founded by Bob Diamond and David Schamis, who, together with their partners, form a complementary partnership with extensive operating and investing expertise across the financial services landscape. For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=RavR7Fh-2OgF2iDH2q-2d_b4BkpkS-nI4ZDTRKxKoX9D15Y9HSy2wqZi3D7YohNfe4NKwpEkM1zpu2aEK7_ZW5X3dMRpIM0H8GX539VNTi-ze1ZTZIBFrFfe4pQHOEBr\" rel=\"nofollow\" target=\"_blank\">www.atlasmerchantcapital.com<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>About Paradigm Operations LP<\/strong>\n      <\/p>\n<p align=\"justify\">Paradigm is a research-driven crypto investment firm that funds companies and protocols from their earliest stages, often when there\u2019s no more than an idea. The firm was founded in 2018 by Matt Huang and Fred Ehrsam on the belief that crypto is driving one of the most important technical and economic shifts of our time, as money, a financial system, and a new internet platform. For more information, please visit www.paradigm.xyz.<\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p align=\"justify\">This press release contains certain statements which are not historical facts, which are forward-looking statements within the meaning of the federal securities laws, for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. These forward-looking statements include certain statements made with respect to the Company\u2019s business, strategy and future plans, as well as the anticipated trading of the Company\u2019s common stock on The Nasdaq Capital Market. These forward-looking statements generally are identified by the words \u201cbelieve,\u201d \u201cproject,\u201d \u201cexpect,\u201d \u201canticipate,\u201d \u201cestimate,\u201d \u201cintend,\u201d \u201cstrategy,\u201d \u201cfuture,\u201d \u201copportunity,\u201d \u201cpotential,\u201d \u201cplan,\u201d \u201cmay,\u201d \u201cshould,\u201d \u201cwill,\u201d \u201cwould,\u201d \u201cwill be,\u201d \u201cwill continue,\u201d \u201cwill likely result,\u201d and similar expressions. Forward-looking statements are predictions, projections and other statements about future events or conditions that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties that could cause the actual results to differ materially from the expected results. These risks and uncertainties include, but are not limited to: changes in business, market, financial, political and regulatory conditions; risks relating to HSI\u2019s anticipated operations and business, including the highly volatile nature of the price of HYPE tokens; the risk that HSI\u2019s stock price will be highly correlated to the price of HYPE tokens and the price of HYPE tokens may decrease; risks related to increased competition in the industries in which HSI will operate; risks relating to significant legal, commercial, regulatory and technical uncertainty regarding HYPE tokens; risks relating to the treatment of crypto assets for U.S. and foreign tax purposes; risks that HSI experiences difficulties managing its growth and expanding operations; challenges in implementing HSI\u2019s business plan including HYPE token-related financial and advisory services, due to operational challenges, significant competition and regulation; and those factors discussed in the final prospectus\/proxy statement (File No. 333-290034) filed by HSI with the Securities and Exchange Commission (the \u201cSEC\u201d) on October 27, 2025, and in subsequent filings and reports made by HSI with the SEC from time to time. While HSI may elect to update these forward-looking statements at some point in the future, HSI specifically disclaims any obligation to do so.<\/p>\n<p>\n        <strong><br \/>\n          <u>Investor Relations Contacts<\/u><br \/>\n        <\/strong>\n      <\/p>\n<p>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=98MwiY2jizsGExaq3f9TaLJs5kP9FOpqW4Ungi6S657t6IVfKxRAdc1OExaDcgXjwE81QqteEBzI77MQX5KrHUbljihY3__cECPmbTQRxni_W2weAMmlBdWYaIRivp-w\" rel=\"nofollow\" target=\"_blank\">investors@hypestrat.xyz<\/a>\n      <\/p>\n<p>\n        <strong><br \/>\n          <u>Media Contacts<\/u><br \/>\n        <\/strong>\n      <\/p>\n<p>Anthony Silverman<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ukCXzCMTDny8OZmbpjiSehm8WxHRTkXxfrYCeaRiOWCQYyV5TVsjdVHLWWHtDmeM6z-G0htAbCVkpfBVEZ7DT9PXy6P-ggXoKXcemR9FoYI=\" rel=\"nofollow\" target=\"_blank\">ads@apellaadvisors.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5NTYwMCM3MzAyNTgwIzIwMTkyOTg=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NTMxNGQ1ZGMtYjRhMi00YWM3LWEzODctZTEyOWMwYTBlNWEzLTEwMzA4NzEtMjAyNS0xMi0wMi1lbg==\/tiny\/Sonnet-BioTherapeutics-Holding.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Hyperliquid Strategies Common Stock Expected to Begin Trading on Nasdaq on Wednesday, December 3 Under the Ticker \u201cPURR\u201d NEW YORK and PRINCETON, N.J., Dec. 02, 2025 (GLOBE NEWSWIRE) &#8212; Hyperliquid Strategies Inc (\u201cHSI\u201d or the \u201cCompany\u201d) and Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) (\u201cSonnet\u201d) today announced the completion of the closing of the previously announced business combination among HSI, Sonnet and Rorschach I LLC (\u201cRorschach\u201d), a newly-formed entity formed by an entity affiliated with Atlas Merchant Capital LLC (\u201cAtlas\u201d), an affiliate of Paradigm Operations LP (\u201cParadigm\u201d), and additional sponsors (all together, the \u201cSponsors\u201d), which was approved by Sonnet\u2019s stockholders on December 2, 2025. As a result of the closing, the Company will operate as a HYPE digital asset treasury reserve &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/hyperliquid-strategies-inc-and-sonnet-biotherapeutics-holdings-inc-announce-closing-of-business-combination\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Hyperliquid Strategies Inc and Sonnet BioTherapeutics Holdings, Inc. Announce Closing of Business Combination&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-915500","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Hyperliquid Strategies Inc and Sonnet BioTherapeutics Holdings, Inc. Announce Closing of Business Combination - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/hyperliquid-strategies-inc-and-sonnet-biotherapeutics-holdings-inc-announce-closing-of-business-combination\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Hyperliquid Strategies Inc and Sonnet BioTherapeutics Holdings, Inc. Announce Closing of Business Combination - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Hyperliquid Strategies Common Stock Expected to Begin Trading on Nasdaq on Wednesday, December 3 Under the Ticker \u201cPURR\u201d NEW YORK and PRINCETON, N.J., Dec. 02, 2025 (GLOBE NEWSWIRE) &#8212; Hyperliquid Strategies Inc (\u201cHSI\u201d or the \u201cCompany\u201d) and Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) (\u201cSonnet\u201d) today announced the completion of the closing of the previously announced business combination among HSI, Sonnet and Rorschach I LLC (\u201cRorschach\u201d), a newly-formed entity formed by an entity affiliated with Atlas Merchant Capital LLC (\u201cAtlas\u201d), an affiliate of Paradigm Operations LP (\u201cParadigm\u201d), and additional sponsors (all together, the \u201cSponsors\u201d), which was approved by Sonnet\u2019s stockholders on December 2, 2025. As a result of the closing, the Company will operate as a HYPE digital asset treasury reserve &hellip; Continue reading &quot;Hyperliquid Strategies Inc and Sonnet BioTherapeutics Holdings, Inc. Announce Closing of Business Combination&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/hyperliquid-strategies-inc-and-sonnet-biotherapeutics-holdings-inc-announce-closing-of-business-combination\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-02T22:29:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5NTYwMCM3MzAyNTgwIzIwMTkyOTg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hyperliquid-strategies-inc-and-sonnet-biotherapeutics-holdings-inc-announce-closing-of-business-combination\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hyperliquid-strategies-inc-and-sonnet-biotherapeutics-holdings-inc-announce-closing-of-business-combination\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Hyperliquid Strategies Inc and Sonnet BioTherapeutics Holdings, Inc. Announce Closing of Business Combination\",\"datePublished\":\"2025-12-02T22:29:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hyperliquid-strategies-inc-and-sonnet-biotherapeutics-holdings-inc-announce-closing-of-business-combination\\\/\"},\"wordCount\":1212,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hyperliquid-strategies-inc-and-sonnet-biotherapeutics-holdings-inc-announce-closing-of-business-combination\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5NTYwMCM3MzAyNTgwIzIwMTkyOTg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hyperliquid-strategies-inc-and-sonnet-biotherapeutics-holdings-inc-announce-closing-of-business-combination\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hyperliquid-strategies-inc-and-sonnet-biotherapeutics-holdings-inc-announce-closing-of-business-combination\\\/\",\"name\":\"Hyperliquid Strategies Inc and Sonnet BioTherapeutics Holdings, Inc. Announce Closing of Business Combination - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hyperliquid-strategies-inc-and-sonnet-biotherapeutics-holdings-inc-announce-closing-of-business-combination\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hyperliquid-strategies-inc-and-sonnet-biotherapeutics-holdings-inc-announce-closing-of-business-combination\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5NTYwMCM3MzAyNTgwIzIwMTkyOTg=\",\"datePublished\":\"2025-12-02T22:29:01+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hyperliquid-strategies-inc-and-sonnet-biotherapeutics-holdings-inc-announce-closing-of-business-combination\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hyperliquid-strategies-inc-and-sonnet-biotherapeutics-holdings-inc-announce-closing-of-business-combination\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hyperliquid-strategies-inc-and-sonnet-biotherapeutics-holdings-inc-announce-closing-of-business-combination\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5NTYwMCM3MzAyNTgwIzIwMTkyOTg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5NTYwMCM3MzAyNTgwIzIwMTkyOTg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hyperliquid-strategies-inc-and-sonnet-biotherapeutics-holdings-inc-announce-closing-of-business-combination\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Hyperliquid Strategies Inc and Sonnet BioTherapeutics Holdings, Inc. Announce Closing of Business Combination\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Hyperliquid Strategies Inc and Sonnet BioTherapeutics Holdings, Inc. Announce Closing of Business Combination - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/hyperliquid-strategies-inc-and-sonnet-biotherapeutics-holdings-inc-announce-closing-of-business-combination\/","og_locale":"en_US","og_type":"article","og_title":"Hyperliquid Strategies Inc and Sonnet BioTherapeutics Holdings, Inc. Announce Closing of Business Combination - Market Newsdesk","og_description":"Hyperliquid Strategies Common Stock Expected to Begin Trading on Nasdaq on Wednesday, December 3 Under the Ticker \u201cPURR\u201d NEW YORK and PRINCETON, N.J., Dec. 02, 2025 (GLOBE NEWSWIRE) &#8212; Hyperliquid Strategies Inc (\u201cHSI\u201d or the \u201cCompany\u201d) and Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) (\u201cSonnet\u201d) today announced the completion of the closing of the previously announced business combination among HSI, Sonnet and Rorschach I LLC (\u201cRorschach\u201d), a newly-formed entity formed by an entity affiliated with Atlas Merchant Capital LLC (\u201cAtlas\u201d), an affiliate of Paradigm Operations LP (\u201cParadigm\u201d), and additional sponsors (all together, the \u201cSponsors\u201d), which was approved by Sonnet\u2019s stockholders on December 2, 2025. As a result of the closing, the Company will operate as a HYPE digital asset treasury reserve &hellip; Continue reading \"Hyperliquid Strategies Inc and Sonnet BioTherapeutics Holdings, Inc. Announce Closing of Business Combination\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/hyperliquid-strategies-inc-and-sonnet-biotherapeutics-holdings-inc-announce-closing-of-business-combination\/","og_site_name":"Market Newsdesk","article_published_time":"2025-12-02T22:29:01+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5NTYwMCM3MzAyNTgwIzIwMTkyOTg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hyperliquid-strategies-inc-and-sonnet-biotherapeutics-holdings-inc-announce-closing-of-business-combination\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hyperliquid-strategies-inc-and-sonnet-biotherapeutics-holdings-inc-announce-closing-of-business-combination\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Hyperliquid Strategies Inc and Sonnet BioTherapeutics Holdings, Inc. Announce Closing of Business Combination","datePublished":"2025-12-02T22:29:01+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hyperliquid-strategies-inc-and-sonnet-biotherapeutics-holdings-inc-announce-closing-of-business-combination\/"},"wordCount":1212,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hyperliquid-strategies-inc-and-sonnet-biotherapeutics-holdings-inc-announce-closing-of-business-combination\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5NTYwMCM3MzAyNTgwIzIwMTkyOTg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hyperliquid-strategies-inc-and-sonnet-biotherapeutics-holdings-inc-announce-closing-of-business-combination\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/hyperliquid-strategies-inc-and-sonnet-biotherapeutics-holdings-inc-announce-closing-of-business-combination\/","name":"Hyperliquid Strategies Inc and Sonnet BioTherapeutics Holdings, Inc. Announce Closing of Business Combination - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hyperliquid-strategies-inc-and-sonnet-biotherapeutics-holdings-inc-announce-closing-of-business-combination\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hyperliquid-strategies-inc-and-sonnet-biotherapeutics-holdings-inc-announce-closing-of-business-combination\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5NTYwMCM3MzAyNTgwIzIwMTkyOTg=","datePublished":"2025-12-02T22:29:01+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hyperliquid-strategies-inc-and-sonnet-biotherapeutics-holdings-inc-announce-closing-of-business-combination\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/hyperliquid-strategies-inc-and-sonnet-biotherapeutics-holdings-inc-announce-closing-of-business-combination\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hyperliquid-strategies-inc-and-sonnet-biotherapeutics-holdings-inc-announce-closing-of-business-combination\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5NTYwMCM3MzAyNTgwIzIwMTkyOTg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5NTYwMCM3MzAyNTgwIzIwMTkyOTg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hyperliquid-strategies-inc-and-sonnet-biotherapeutics-holdings-inc-announce-closing-of-business-combination\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Hyperliquid Strategies Inc and Sonnet BioTherapeutics Holdings, Inc. Announce Closing of Business Combination"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/915500","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=915500"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/915500\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=915500"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=915500"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=915500"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}